Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Admin Promises More ‘Aggressive’ Approach To False Claims Act Enforcement, Lawyers Say

Executive Summary

Manufacturers may see a more forceful approach toward False Claims Act enforcement under the new administration, attorneys say.

You may also be interested in...



FCA: 2020 Sees More False Claims Cases Than Ever While Recoveries Plummet

A report from the law firm Gibson Dunn found that the US government brought more new cases under the False Claims Act last year than ever before, which they partially attribute to COVID-19 enforcement actions.

False Claims Act Update Finds More Clarity On 'Escobar'

Courts have been busy with False Claims Act-related cases in the first half of 2018 despite a lack of device-specific settlements, new analysis from law firm Gibson Dunn shows. Of particular interest: New rulings that show courts settling on a unified interpretation of the Supreme Court’s 2017 Escobar ruling.

DOJ Memo Could Offer Additional Defenses In Enforcement Actions

Industry should be cautious in interpreting a recent US Department of Justice memo stating DOJ wouldn’t take enforcement actions based on failure to comply with guidance documents alone, according to experts. But the document still could offer assistance to manufacturers fighting enforcement actions.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel